Moberg Pharma AB

Moberg Pharma is a Swedish specialty pharmaceutical company in the commercial stage, active in dermatology. It has developed MOB-015 (Terclara®), a topical terbinafine formulation for mild-to-moderate nail fungal infections in adults. Terclara received national approval in Sweden (first country for OTC approval) and was recommended for approval in 13 European countries in 2023. Phase III trials showed superior mycological cure rate (76% vs 42% for comparators). Listed on Nasdaq First North.